Episurf Medical planned the 700th surgery with Episealer® knee implants for the treatment of cartilage lesions and underlying bone damage.
“This is becoming a significant patient population and we look forward to seeing more clinical evidence from this group of patients. The use of the Episealer is definitely increasing and in Q1 2020, we have already exceeded the average quarterly volumes from 2019, indicating that also our customers are becoming more and more comfortable with this new treatment method,” said Pål Ryfors, Chief Executive Officer.
Episurf Medical planned the 700th surgery with Episealer® knee implants for the treatment of cartilage lesions and underlying bone damage.
Reported revision rates remain low, and presented clinical data shows significant improvements for Episealer recipients. About 275 patients have had the implant for more than two years. Of those, 25...
Episurf Medical planned the 700th surgery with Episealer® knee implants for the treatment of cartilage lesions and underlying bone damage.
“This is becoming a significant patient population and we look forward to seeing more clinical evidence from this group of patients. The use of the Episealer is definitely increasing and in Q1 2020, we have already exceeded the average quarterly volumes from 2019, indicating that also our customers are becoming more and more comfortable with this new treatment method,” said Pål Ryfors, Chief Executive Officer.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.